You are here

Noxafil Delayed-Release Tablets Approved

New formulation for prevention of Aspergillus and Candida infections (November 26)

A new formulation for posaconazole (Noxafil, Merck) 100 mg delayed-release tablets has been approved. Patients take a loading dose of 300 mg (three 100-mg delayed-release tablets) twice daily on the first day, followed by a once-daily maintenance dose of 300 mg (three 100-mg delayed-release tablets) starting on the second day of therapy.

Merck also sells a 40-mg/mL oral suspension, which is taken three times daily.

The delayed-release tablets and oral suspension are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age and older with a severely compromised immune system, such as hematopoietic stem-cell transplant recipients with graft-versus-host disease or those with hematological malignancies with prolonged neutropenia resulting from chemotherapy.

Posaconazole delayed-release tablets and the oral suspension are not to be used interchangeably because of differences in the dosing of each formulation.

[Source: Merck; November 26, 2013.]

Recent Headlines

Medical Device Enables Nerve Stimulation During Sleep
May Offer Improved Safety Profile for Pediatric Patients
Hope for Sufferers With Post-Treatment Lyme Disease Syndrome
KardiaMobile Receives Two More Clearances for Arrhythmia Detection
Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable